Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?

This scientific commentary refers to ‘No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer’s disease and related dementia: results from the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study’ by Desai et al. (https://doi.org/10.1093/brain...

Descripción completa

Detalles Bibliográficos
Autor principal: Newby, Danielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Scientific Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598549/
https://www.ncbi.nlm.nih.gov/pubmed/36324868
http://dx.doi.org/10.1093/braincomms/fcac260
_version_ 1784816361389686784
author Newby, Danielle
author_facet Newby, Danielle
author_sort Newby, Danielle
collection PubMed
description This scientific commentary refers to ‘No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer’s disease and related dementia: results from the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study’ by Desai et al. (https://doi.org/10.1093/braincomms/fcac247)
format Online
Article
Text
id pubmed-9598549
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95985492022-11-01 Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias? Newby, Danielle Brain Commun Scientific Commentary This scientific commentary refers to ‘No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer’s disease and related dementia: results from the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study’ by Desai et al. (https://doi.org/10.1093/braincomms/fcac247) Oxford University Press 2022-10-11 /pmc/articles/PMC9598549/ /pubmed/36324868 http://dx.doi.org/10.1093/braincomms/fcac260 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Scientific Commentary
Newby, Danielle
Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
title Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
title_full Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
title_fullStr Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
title_full_unstemmed Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
title_short Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
title_sort are phosphodiesterase type 5 inhibitors potential therapies for alzheimer’s disease and related dementias?
topic Scientific Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598549/
https://www.ncbi.nlm.nih.gov/pubmed/36324868
http://dx.doi.org/10.1093/braincomms/fcac260
work_keys_str_mv AT newbydanielle arephosphodiesterasetype5inhibitorspotentialtherapiesforalzheimersdiseaseandrelateddementias

Ejemplares similares